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Abstract
For the treatment choice of localized prostate cancer, effective patient decision aids have been developed. 
The implementation of decision aids in routine care, however, lags behind. Main known barriers are lack of 
confidence in the tool, lack of training on its use, lack of resources and lack of time. A new implementation 
strategy addresses these barriers. Using this implementation strategy, the implementation rate of a decision 
aid was measured in eight hospitals and questionnaires were filled out by 24 care providers and 255 patients. 
The average implementation rate was 60 per cent (range 31%–100%). Hardly any barriers remained for 
care providers. Patients who did not use the decision aid appeared to be more unwilling than unable to use 
the decision aid. By addressing known barriers, that is, informing care providers on the effectiveness of the 
decision aid, providing instructions on its use, embedding it in the existing workflow and making it available 
free of charge, a successful implementation of a prostate cancer decision aid was reached.
Keywords
decision aid, implementation, implementation barriers, implementation strategy, prostate cancer, shared 
decision-making, treatment choice
Background
For primary localized prostate cancer, different treatment modalities are available: active surveil-
lance, surgery, interstitial radiotherapy (brachytherapy) and external beam radiotherapy. For most 
patients with localized tumours, current guidelines do not indicate one ‘best’ option.1,2 The treat-
ments are comparable for survival, but differ with respect to side effects. This implies that patient 
values and preferences should play a key role. A useful tool to involve patients in the choice of their 
treatment is a decision aid (DA).
A DA is a tool (booklet or website) with two goals: (1) to inform patients about the risks and ben-
efits of their treatment options and (2) to stimulate patients to consider which risks or benefits are 
most important for them. According to the International Patient Decision Aid Standards (IPDAS), 
DAs should at least contain the following main elements: explaining the fact that there is a decision 
to be made, describing the treatment options with their pros and cons and helping patients to make a 
personal trade-off by presenting the pros and cons in a structured and balanced way.
DAs appear to have effects on patients, as shown in Lin et al.3 and Stacey et al.4 DAs lead to more 
knowledge about treatments, more realistic expectations and more shared decision-making without 
increasing anxiety or regret. With DA, patients are more certain about the choice, the choice reflects 
what matters to the patient and fewer patients want intensive treatment.3,4 Although some patients 
prefer to leave the decision to the physician, the vast majority of patients consider it a good idea to be 
offered the possibility to choose, even of patients who decline to make their own treatment choice.5
Given the fact that DAs have been shown to be effective, more effort needs to be made to imple-
ment this evidence6 as the implementation of DAs in routine care lags behind.7 To date, many 
patients who are eligible for more than one treatment option, do not receive a DA. A systematic 
implementation strategy aims to improve this. According to the model by Grol,8 for successful 
implementation, different players in health care should be involved, interventions should be 
adapted to local needs and barriers to change should be identified. Literature reviews have identi-
fied barriers for implementation of DAs; main barriers reported by physicians were lack of confi-
dence in the content, lack of training on how to use decision support, fear of disruption of the 
workflow, time constraints, low accessibility and high cost.7,9–11 For example, a recent study con-
cluded that implementation would be facilitated by informing professionals about the positive 
effects of the DA and by embedding the DAs in the existing workflow.12
We designed an implementation strategy for DAs, in which we incorporated the implementation 
lessons from earlier studies.7,9–11 The implementation strategy described in this study applies to 
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both web-based and printed DAs. The strategy focuses on removing identified barriers. Respectively, 
lack of confidence, lack of skills, fear of workflow disruption, time concerns, accessibility and cost 
are addressed (see the ‘Methods’ section for more details). This implementation strategy was used 
to implement a recently developed DA booklet for localized prostate cancer.13,14 DAs have been 
shown to be equally effective in web-based and in paper format.15,16
In short, we developed and applied a strategy to achieve implementation of a DA, aiming to 
provide DAs to as many eligible patients as possible. Eligible patients are all patients who have 
more than one treatment option to choose from. Aim of our study was to measure the implementa-
tion rate of this tool, when using the implementation strategy. To date, studies lack information on 
the implementation rate that was actually achieved.7 Second, as the usage of DAs is determined both 
by professionals providing DAs and by patients using those DAs, we aim to identify remaining bar-
riers and facilitators for use of the DA as perceived by both health care professionals and patients.
Methods
The implementation rates of a DA for prostate cancer were calculated per hospital, and barriers for 
both care providers and patients were assessed by questionnaire.
Implementation strategy
The implementation strategy is presented in Table 1. Barriers that were identified in the literature 
were taken into account. (1) Lack of confidence in the content was addressed, in each participating 
hospital, by explaining the content of the DA to the care providers, together with the results of a 
randomized trial13,14 showing its effectiveness. (2) To reduce chance of disruption of workflow, 
local health care professionals were involved in the logistic decisions on how to best embed the DA 
in the existing care path in their own hospital. (3) To address accessibility and cost barriers, the 
DAs were provided to the hospitals free of charge. (4) To address the lack of training on how to use 
Table 1. Implementation strategy.
1.  Inform and create support for use of the decision aid (DA). In each participating hospital, the DA was 
presented, together with the results of a randomized trial showing its effectiveness.
2.  Document the current care path to find the best way, in consultation with the health care professionals, to 
incorporate the decision aid in the existing care path. This involved both the timing of the DA (directly 
following the diagnosis or later) and the health care professional to present it (urologist or specialized 
nurse).
3.  Address cost and accessibility of the DA. In this study, the booklets were made available to the hospitals 
free of charge.
4.  Provide a short written instruction for professionals who present the DA to the patients. This instruction 
(on a plasticized card) listed the following steps: (1) explain there is a treatment choice, (2) indicate 
which options are open to the patient, (3) describe options with pros and cons, (4) answer questions 
and (5) stimulate patients to consider their preference.
5.  Appoint a contact per hospital. This could be a urologist, or any other person (nurse, administrator), who 
is committed and keeps track of the use of the DA.
6.  Support the initial implementation by weekly telephone or mail checkups with the contact, to clear 
possible questions or problems.
7.  Gradually reduce the support, so that the implementation is eventually carried by the hospital itself.
8.  Send quarterly news updates to all participating care professionals (monitor and feedback).
9.  Survey barriers and facilitators in both patients and health care professionals.
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decision support, the following instructions for the use of the DA were incorporated in the above 
presentations: (a) make clear there is a treatment choice to be made, (b) identify the treatment 
options for this individual and mark these in the DA booklet, (c) discuss pros and cons of each 
option, (d) stimulate the patient to think about which pros and cons are most important to him, (e) 
give the DA with this information to take home, allow the patient some time to consider, (f) dis-
cuss, and reach a shared decision. These instructions were also handed out to the health care pro-
fessionals on plasticized cards at the start of the implementation phase. As shown in Table 1, our 
implementation strategy also included several monitoring and feedback steps (step 5 through step 
8) and a survey of other potential barriers and facilitators (step 9).
Procedure
We studied the implementation of a DA for localized prostate cancer. This DA has been shown to 
improve patients’ knowledge and participation in decision-making13 without inducing anxiety or 
regret.14 It consists of a booklet to be used during the consultation and to take home for further con-
sideration. The booklet describes the treatments, it compares outcome information, that is, the likeli-
hood of cure and of the side effects associated with each treatment, and a table listing the pros and 
cons of each treatment. The outcome information is presented for two risk groups: (A) Gleason ⩽ 7 
and prostate-specific antigen (PSA) ⩽ 20 and T1T2 or (B) Gleason > 7 and/or PSA > 20 and/or T3. 
On a dedicated first page of the DA booklet, the care provider indicated which treatment options are 
open to this individual patient and which risk information applied (A or B). The DA booklets were 
distributed to the hospitals. Care providers were asked to hand out and go through the DA with each 
eligible patient, according to the instructions described above as item 4 of the implementation strat-
egy. All patients who have more than one treatment option are eligible. The only exclusion criterion 
is insufficient Dutch language proficiency. Depending on the local care path, this could be done by 
a urologist or a specialized nurse. In addition, the care provider asked patients whether a researcher 
could contact them about the study. The care provider documented whether or not the patient agreed 
with the telephone call and gave this information to the researcher. The researcher (J.J.v.T.-G.) 
explained the aim of the study to the patients by telephone and, after verbal informed consent, sent 
a written consent form, a questionnaire and a reply-paid envelope.
Questionnaires
Health care professionals filled out an online questionnaire after using the DA for a period of 6 to 8 
months. This questionnaire was based on the MIDI tool,17 which identifies barriers and facilitators at 
the level of the innovation (DA), the user (health care professional) and the organization (hospital).
Patients filled out a questionnaire 2 weeks after they received the DA. It contained questions on 
the presentation and content of the DA, whether they had used the DA and possible barriers and 
facilitators for the use of the DA.
Analyses
Our primary outcome measure was the implementation rate per hospital per year. The implementa-
tion rate per hospital was defined as the number of patients who received the DA divided by the 
number of eligible patients as estimated from a registry. More precisely, for the numerator, patients 
were counted who received the DA and who were also enrolled in the study. For the denominator 
(number of eligible patients), hospital-specific data were extracted from the National Cancer 
Registry of the Netherlands (IKNL). The number of patients with prostate cancer, excluding 
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clinical T4, N+ and M+, were counted per hospital over the preceding 6 years and corrected for 
the duration of inclusion.
Barriers for care providers who used the DA 10 times or less were compared to colleagues who 
used the DA more often. For each barrier of facilitator, the percentages of care providers that endorsed 
it were analysed using chi-square tests. Patients who did or did not use the DA were also compared 
using chi-square tests. To correct for the number of barriers and facilitators tested, a Bonferroni cor-
rection was applied by dividing the significance level α by the number of barriers/facilitators.
Results
Patients and health care professionals
Ten hospitals in the region were asked to participate in the study, of which eight hospitals agreed. 
Two declined because they already participated in a study on DAs. Between spring of 2013 and 
summer of 2014, 30 health care professionals presented the DA to 316 patients. Of these patients, 
11 were not eligible for the study, because additional diagnostics showed they had tumour growth 
outside of the prostate (N = 8) or had other health issues (N = 3) which meant they did not have a 
choice of treatment options. Of the remaining 305 patients, 294 (96%) gave informed consent and 
255 (84%) returned the questionnaire. Of the 30 health care professionals, 24 filled out their ques-
tionnaire, representing a response rate of 80 per cent. The characteristics of the participating 
patients and care providers are listed in Table 2.
Implementation rate
Table 3 presents the estimated implementation rate of the DA. The number of patients who received 
the DA and were enrolled in the study in each hospital (A) was divided by the estimated number of 
eligible patients in each hospital (B). Since one hospital did not give permission to obtain registry 
data, the results are presented for seven of the eight hospitals. Overall, the average implementation 
rate was 60 per cent, ranging from 31 to 100 per cent.
Evaluation by health care professionals
The reception of the DA by the health care professionals was positive. They rated its value 8.1 
(range = 6–9) on a scale from 1 to 10.
Presenting the DA. The vast majority of care providers reported that, when presenting the DA, they 
explained to patients that there were different treatment options, indicated which options were 
open for the patient and stimulated the patient to consider the pros and cons and make a personal 
trade-off (96%–100%). Most providers (88%) reported having asked their patients for their prefer-
ence after the patients had gone over the DA.
Barriers and facilitators. The majority of health care professionals (92%) stated that they had offered 
the DA to all eligible patients. Those who had not always offered the DA endorsed various reasons 
which were related to logistics (somebody else offered the DA), physician-related (I forgot) or 
patient-related (patient nervous, already decided, unwilling). Time constraints did not appear to be 
an important factor; some care providers indicated that the DA required extra time (17%), but most 
answered neutrally (71%) or agreed with the statement that the DA saved time (13%). Moreover, 
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none of the care professional indicated that they ‘lacked the time’ to offer the DA. An open ques-
tion yielded no additional barriers.
Table 4 shows the percentages of care providers who endorsed potential barriers and facilitators. 
Most professionals disagreed with the negative statements (suggested barriers) and agreed with the 
positive statements (suggested facilitators). The facilitator that was endorsed by all care providers 
Table 2. Characteristics of the professionals and patients who filled out the questionnaires.
Characteristics of care professionals (N = 24) N (%)
Urologist 16 (67)
Oncology nurse 8 (33)
Working in:
University hospital 5 (21)
Other urology training hospital 6 (25)
General hospital 13 (54)




Age (years), mean (SD) 66 (6)
Pre-existing urinary problems 37




Gleason ⩽ 7 90
PSA ⩽ 10 73
SD: standard deviation; PSA: prostate-specific antigen.
Table 3. Estimated minimal implementation rate.
Hospital Number of patients who received a 
DA (and enrolled in the study)
A





1 45 144 31
2 45 79 57
3 78 90 87
4 28 47 60
5 7 19 37
6 54 43 100
7 27 48 56
8b – – –
Total 284 470 60%
DA: decision aid.
aEstimated from national registry data per hospital over a 6-year period.
bHospital 8 did not give permission to obtain registry data on their number of eligible patients.
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(100%) was ‘Offering the DA fits well with the existing guidelines and procedures’. After 
Bonferroni correction, no significant difference was found between care professionals who pre-
sented the DA to more than 10 patients versus those who presented the DA to less patients.
Evaluation by patients
Use of the DA. Of the 255 patients who received the DA, 88 per cent indicated that they had used 
the DA (N = 225) and 12 per cent that they had not used it (N = 30). Users were comparable to non-
users for demographic characteristics, such as age (66.1 ± 6 vs 65.1 ± 6, p = .36), marital status 
Table 4. Agreement with facilitators and barriers for professionals who were high DA providers (to 
more than 10 patients) versus low DA providers (to 10 patients or less).








It is clear to me what needs to be done, and 
in which order, when presenting the DA
92 82 .44
The DA is based on correct information 85 91 .64
The DA contains all the information 
necessary to use it
92 82 .44
The DA fits well with how I usually work 85 91 .64
I clearly notice the effects of using the DA 46 55 .68
I consider the DA appropriate for/applicable 
to all patients with localized prostate cancer, 
who have a choice between two or more 
treatment options
92 91 .90
The DA is based on current knowledge 85 91 .64
The information in the DA is complete 85 91 .64
The DA is practical to use 100 91 .27
The DA saves me time 23 0 .09
The DA made it easier to discuss the 
treatment options with my patient
62 82 .28
The DA makes my patients more satisfied 
with the information provision
54 73 .34
Offering the DA is compatible with the 
existing guidelines and procedures
100 100 –
Barriers
The DA is too complex for professionals to 
use
15 9 .64
The DA is biased towards a particular 
treatment option
31 0 .04
Active surveillance should get more 
attention in the DA
62 36 .22
My trust in the DA is insufficient 8 18 .44
Using the DA is bothersome for my patients 0 0 –
DA: decision aid.
aHigh providers: offered the DA to more than 10 patients.
bLow providers: offered the DA to 10 patients or less.
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(12% vs 10%, single, p = .73) and tumour characteristics (90% vs 90%, Gleason score ⩽ 7, p = .95 
and 70% vs 77%, PSA ⩽ 10, p = .69). A difference was found for education; more users had a col-
lege degree than non-users (41% vs 20%, p = .028).
Barriers and facilitators. The barriers and facilitators that users and non-users endorsed are listed in Table 
5. Clearly, non-users experienced more barriers and less facilitators compared to users. After Bonferroni 
correction, 11 barriers/facilitators still differed significantly between users and non-users (Table 5).
Of the users, 83 per cent said that the DA had ‘much’ or ‘very much’ added value compared to 
other information they had received, and all (100%) would recommend the DA to others. The evalu-
ation of the decision-making process was also positive. Most patients found it meaningful (97%) and 
desirable (89%) to be involved in the treatment choice. It was easy for most patients to reach a deci-
sion (83%), and most patients felt no pressure during the decision-making process (98%).
Content of the DA. Patients were positive about the content of the DA. The information was clear 
(98%), complete (84%) and easy to use (96%). Most patients (95%) indicated that the information 
about the different treatment options was balanced. To the question how often words were unknown, 
Table 5. Agreement with facilitators and barriers for patients who used the DA versus those who did 









The DA is too difficult 2 12 .005
Too directive towards a specific treatment 9 8 .97
The DA is unclear 1 8 .026
The DA is not practical 3 15 .002*
Lack of trust 6 28 <.001*
Nothing to gain from it 4 24 <.001*
Too bothersome 5 8 .44
Lack of motivation 3 19 <.001*
Would increase my uncertainty 5 19 .009
Insufficiently adapted to my specific needs 11 20 .22
Facilitators
The DA is a pleasure to use 95 54 <.001*
Facilitates treatment comparison 94 54 <.001*
Provides insight in pros and cons 94 68 <.001*
Information is complete 85 67 .056
I believe the DA can help me decide 88 54 <.001*
Would reduce my uncertainty 72 42 .009
My choice was made with the DA 76 33 <.001*
I liked using the DA as an additional source 
of information
96 71 <.001*
Facilitates talking with family and friends 86 58 .003
Facilitates talking with my care provider 84 54 .002*
DA: decision aid.
*Significant after Bonferroni correction for number of tests: α = .05/20 = .0025.
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the content was too complicated or they needed someone else to help them understand the text, 
almost all patients (96%) responded that this was rarely or never the case.
Presenting the DA (by whom and when). Most patients were satisfied with the way the DA was 
applied by the health care professionals. Table 6 shows that the DA was presented most frequently 
by the urologist (79%, N = 181) and less often by the oncology nurse (21%, N = 47). The urologist 
was considered the most appropriate person to do so, according to the vast majority (97%) of 
patients who received it from the urologist. However, of the patients who received the DA from the 
nurse, a majority (64%) considered the nurse to be the most appropriate person.
Most patients (59%) received the DA on the same day as their diagnosis of prostate cancer. 
Other patients received the DA either 1 day to 1 week after diagnosis (10%), 1 to 2 weeks after 
diagnosis (12%) or more than 2 weeks after diagnosis (19%). Whether patients felt that they had 
received the DA at the appropriate moment is shown in Figure 1. Of the patients who received the 
DA on the day of diagnosis, 1 per cent would have preferred to receive it later. Of the patients who 
received it 1 day to 1 week after diagnosis, all considered this the appropriate time to receive the 
DA. After more than 1 week, some patients would have preferred to receive the DA earlier.
Most patients (89%) indicated that the care provider had asked for their treatment preference. 
Almost all indicated that they had felt sufficient opportunity to discuss their preference with the 
professional (95%) and to get their questions answered (92%).
Discussion
The implementation strategy, used in this study, yielded an implementation rate of 60 per cent on 
average over eight hospitals. The strategy reduced previously identified barriers for implementa-
tion. No additional barriers were identified from the care providers’ perspective or from the 
patients’ perspective. The DA was well received by patients and care professionals. Patients con-
sidered both physicians and nurses to be appropriate professionals to hand out the DA. Receiving 
the DA on the same day as the diagnosis was acceptable to almost all patients.
Below, we will discuss the results regarding the implementation rates, the barriers and facilita-
tors, first from the physicians’ point of view and second from the patients’ point of view. Finally, 
we will discuss the incorporation of DAs in the care pathway.
Successful implementation
The estimated implementation rate was higher than expected, that is, 60 per cent. Still, this may be 
a conservative estimate. It was calculated using the number of patients who received the DA and 
who were also enrolled in the study. This may have resulted in an underestimation of the actual 
implementation rate, since not all patients receiving the DA may have been enrolled in the study. 
Table 6. Most appropriate professional to present DA according to patients.
Who presented the DA to you? Urologist most appropriate Nurse most appropriate
Urologist (N = 181) 97% 3%
Specialized nurse (N = 47) 36% 64%
DA: decision aid.
Questions asked were as follows: (1) Who presented the DA to you? (2) Who do you consider to be the most appro-
priate professional to do so?
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Indeed, roughly twice as many DAs were used from stock by the participating hospitals as there 
were patients included in the study.
It is hard to compare the average implementation rate of 60 per cent with implementation rates 
achieved in other settings. Surveys in the Unites States on implementation of DAs showed that 
about one-third of physicians reported using a DA.18,19 These studies, however, do not report an 
implementation rate, that is, an estimate on how many of the eligible patients received a DA. One 
study on the use of a DA for cystic fibrosis patients reported an exceptional 95 per cent implemen-
tation rate, but this was self-reported by care providers and could not be verified in patients or 
otherwise.20 A systematic review of 17 studies on the implementation of patient decision support 
reported a lack of specific information about the implementation rates that were achieved.7
This study measured the implementation rate that was attained and, as such, adds to the exist-
ing literature in which such data are lacking. It is important to measure the attained implementa-
tion rate, as a considerable gap has been reported between physician’s intention to adopt DAs 
and their actual behaviour.18 This intention–behaviour gap may underlie the poor implementa-
tion in some hospitals.
In this study, a large variation in implementation rates was found between hospitals. No obvious 
reasons for this variation were found. The type of hospital, university or regional, large or small, 
was not related to implementation rates. After 2 years, the DAs were reportedly still used by all 
eight participating hospitals. In one hospital, the use of the DA was reduced in comparison with the 
study period. Two other hospitals reported an increase in implementation rate, as their care 
Figure 1. Timing and satisfaction with timing of the decision aid.
N  indicates the number of patients.
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pathway was reorganized and the DAs were now handed out by a dedicated nurse who saw all 
patients with prostate cancer. Underlying reasons for the variation in implementation rates will be 
further explored by interviews.
Barriers and facilitators
Some care providers indicated that the DA required extra time, but most answered neutral or even 
agreed that the DA saved time. In other settings, 20 to 32 per cent of the physicians also agreed that 
DAs will save time.18 The main facilitating factor for the care providers in this study turned out to 
be its agreement with the guidelines. Guidelines do urge the use of shared decision-making.2,21 
However, it would be even more helpful if, in addition, they would support the use of DAs more 
explicitly, as this might ensure greater adoption of DAs.19
A recent survey in urologists and radiation oncologist showed that most were familiar with 
DAs. Still, only a minority used them in daily care. An important barrier for professionals who did 
not use DAs was the assumption that patients could not process information from DAs.19 This 
assumption was not supported by the data of the patients in our study, since 96 per cent indicated 
that the content of the DA was not too complicated and that they did not need someone else to help 
them understand.
For patients, other barriers have been reported in literature. To participate in shared decision-
making, patients do not only need knowledge but also need to be empowered to participate.22 DAs 
that solely focus on the provision of information fail to address the acceptability and need for 
patient involvement. A review of 44 studies revealed that patient barriers include a lack of percep-
tion that there is a preference-sensitive decision to be made, incorrect timing of receiving the DA 
and physicians who do not inquire about patients’ preferences or needs.23 In our study, the DA and 
the instructions for care providers on when and how to engage patients appear to have reduced such 
barriers. The patients overwhelmingly agreed with the suggested facilitators and hardly agreed 
with the suggested barriers.
The differences in endorsed barriers between patients that were users versus non-users do not sug-
gest that non-users were unable to use the DA; barriers such as ‘too difficult/unclear/insufficiently 
adapted to my needs/information is (not) complete’ were not endorsed more by non-users. Instead, 
non-users appear to be unwilling or unmotivated to use the DA; significantly more often, they 
endorsed barriers such as lack of trust/lack of motivation/(not) believe the DA can help me decide. 
This suggests that the use of DAs could be increased by explaining the potential benefits more clearly 
to patients. Here, the care providers could potentially play a role in motivating their patients.
In all, most barriers were removed by the implementation strategy, for both care providers and 
patients. This confirms the notion that barriers are modifiable rather than fixed.23 This is important 
because in physicians treating prostate cancer, a strong relation was found between their endorsement 
of barriers and their actual application of DAs.19 Our study suggests that using an implementation 
strategy that takes known barriers into account may result in adoption of DAs for prostate cancer.
Implementation strategy
Designing implementation strategies is challenging. Successful implementation requires active tar-
geting of the users, that is, health care providers and patients.24 It is known that successful imple-
mentation requires tailored interventions based on identified barriers.25 The implementation 
strategy, used in this study, involved reducing previously identified barriers for implementation. 
Our study did not reveal any additional barriers or facilitators that could be incorporated in adapt-
ing or optimizing our strategy. The strategy resulted in a satisfactory implementation rate. Since the 
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introduction of the DA was well received by both patients and care professionals, this strategy may 
be useful for other clinical contexts using DAs as well.
How and when to implement the DA in the care pathway
The first week after diagnosis appears to be the preferred moment for patients to receive a DA. 
Even the day of diagnosis was considered an appropriate time by almost all patients who had 
received the DA on the day of diagnosis.
The experience with delivery of the DA by a nurse appears to make patients more appreciative 
of delivery by the nurse. This fits well in a recent development; a growing number of hospitals in 
the Netherlands allot a role to specialized nurses in informing patients about their treatment options.
Limitations
To calculate the implementation rate, the estimated number of eligible patients was derived from 
historic data (i.e. the mean number of eligible patients per year in the participating hospitals in the 
preceding 6 years). Although no trend was found over those years, the number of eligible patients 
may have changed.
All data on decision-making were self-reported by patients and physicians. There were no video 
or audio recordings of the consultations to confirm whether care providers followed all instructions.
Another limitation may be the selection bias professionals and patients who are not inter-
ested in using DAs may have been less willing to fill out the questionnaire and may have had a 
different opinion on the barriers.26 This is a common bias in studies on health care innovations. 
Please note that the implementation rates in our study are not based on the questionnaires and 
are calculated for the entire urology departments, including the patients of possibly reluctant 
care providers.
Conclusion
A successful implementation of a DA on prostate cancer can be reached, by addressing known bar-
riers. By informing caregivers on the effectiveness of the DA, by providing instructions on its use, 
by embedding it in the existing workflow and by making it available free of charge, implementa-
tion barriers were strongly reduced. This article may help to facilitate the implementation of DAs, 
both paper-based and online versions, in daily practice.
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